Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies.

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY

Current Neurology and Neuroscience Reports Pub Date : 2023-09-01 DOI:10.1007/s11910-023-01289-9

W Daniel Chapman, Megan C Herink, Michelle H Cameron, Dennis Bourdette

{"title":"Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies.","authors":"W Daniel Chapman, Megan C Herink, Michelle H Cameron, Dennis Bourdette","doi":"10.1007/s11910-023-01289-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: Polypharmacy, the use of ≥ 5 medications, is common in people with multiple sclerosis and is associated with negative outcomes. The use of multiple medications is common for symptom management in people with multiple sclerosis, but risks drug-drug interactions and additive side effects. Multiple sclerosis providers should therefore focus on the appropriateness and risks versus benefits of pharmacotherapy in each patient. This review describes the prevalence and risks associated with polypharmacy in people with multiple sclerosis and offers strategies to identify and mitigate inappropriate polypharmacy.Recent findings: Research in people with multiple sclerosis has identified risk factors and negative outcomes associated with polypharmacy. Medication class-specific investigations highlight their contribution to potentially inappropriate polypharmacy in people with multiple sclerosis. People with multiple sclerosis are at risk for inappropriate polypharmacy. Multiple sclerosis providers should review medications and consider their appropriateness and potential for deprescribing within the context of each patient.","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Neurology and Neuroscience Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11910-023-01289-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Polypharmacy, the use of ≥ 5 medications, is common in people with multiple sclerosis and is associated with negative outcomes. The use of multiple medications is common for symptom management in people with multiple sclerosis, but risks drug-drug interactions and additive side effects. Multiple sclerosis providers should therefore focus on the appropriateness and risks versus benefits of pharmacotherapy in each patient. This review describes the prevalence and risks associated with polypharmacy in people with multiple sclerosis and offers strategies to identify and mitigate inappropriate polypharmacy.

Recent findings: Research in people with multiple sclerosis has identified risk factors and negative outcomes associated with polypharmacy. Medication class-specific investigations highlight their contribution to potentially inappropriate polypharmacy in people with multiple sclerosis. People with multiple sclerosis are at risk for inappropriate polypharmacy. Multiple sclerosis providers should review medications and consider their appropriateness and potential for deprescribing within the context of each patient.

Abstract Image

查看原文本刊更多论文

多发性硬化症的多重用药:患病率、风险和缓解策略。

综述目的:多重用药，即使用≥5种药物，在多发性硬化症患者中很常见，并与负面结果相关。多发性硬化症患者通常使用多种药物治疗症状，但存在药物相互作用和附加副作用的风险。因此，多发性硬化症提供者应关注每个患者药物治疗的适宜性和风险与益处。这篇综述描述了多发性硬化症患者多重用药的患病率和相关风险，并提出了识别和减轻不适当多重用药的策略。最近的发现:对多发性硬化症患者的研究已经确定了与多药相关的危险因素和负面结果。药物类别特异性调查强调了它们对多发性硬化症患者可能不适当的多药治疗的贡献。多发性硬化症患者存在不适当的多药治疗风险。多发性硬化症的提供者应该审查药物，并考虑他们的适当性和潜在的在每个病人的情况下开处方。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Neurology and Neuroscience Reports 医学-临床神经学

CiteScore

9.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Neurology and Neuroscience Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the diagnosis, treatment, management, and prevention of neurological disease and disorders. Presents the views of experts on current advances in neurology and neuroscience Gathers and synthesizes important recent papers on the topic Includes reviews of recently published clinical trials, valuable web sites, and commentaries from well-known figures in the field.